Evidence map›Paper›PMID 41622258›Full record

ArticleJournal of nanobiotechnology2026

Morphology-driven zinc oxide biointeractive carriers with biological barrier modulating effects for pulmonary delivery of liraglutide.

Jin-Hyuk Jeong, Chang-Soo Han, Ji-Hyun Kang, Dong-Wook Kim, Chun-Woong Park

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jin-Hyuk JeongCollege of Pharmacy, Chungbuk National University, Cheongju, 28160, Republic of Korea.
Chang-Soo HanP2KBio, Cheongju, 28160, Republic of Korea.
Ji-Hyun KangInstitute of New Drug Development, and Respiratory Drug Development Research Institute, School of Pharmacy, Jeonbuk National University, Jeonju, 54896, Republic of Korea.
Dong-Wook KimCollege of Pharmacy, Wonkwang University, Iksan, 54538, Republic of Korea.
Chun-Woong ParkCollege of Pharmacy, Chungbuk National University, Cheongju, 28160, Republic of Korea. cwpark@cbnu.ac.kr.

Funding

Ministry of Education, South korea 2025-RISE-11-014-03Ministry of Health & Welfare, South korea RS-2024-00335798Ministry of Science and ICT, South Korea NRF-2021R1A2C4002746
6 · The paper itself

Abstract

Pulmonary delivery provides a noninvasive route for systemic administration of biologics, yet efficient lung deposition and permeation across pulmonary barriers remain major challenges. In this study, morphology-engineered zinc oxide (ZO) biointeractive carriers were fabricated and evaluated as inhalable carriers for liraglutide (LG). Three distinct morphologies were obtained: smooth spherical ZO-1 (5-7 μm), spiky sea-urchin-like ZO-2 (5-8 μm with elongated ~ 3.5 μm tips), and compact spiky ZO-3 (1-3 μm with short ~ 1.3 μm tips). Particle image velocimetry (PIV) revealed morphology-dependent aerodynamic behaviors, where ZO-3 exhibited turbulence-driven dispersion favoring distal lung deposition. At the cellular level, ZO-3 demonstrated enhanced mucus penetration and reduced macrophage uptake, maintaining prolonged contact with the epithelial surface. Following intratracheal administration, LG@ZO-3 achieved bioavailability of ~ 60% relative to subcutaneous injection in healthy rats and ~ 51% in diabetic rats, far exceeding the < 2% oral bioavailability of semaglutide. These results suggest that morphology-controlled modulation of aerodynamic and biological interactions can overcome multiple pulmonary barriers, offering a promising strategy for effective inhalable delivery of peptide therapeutics.

Indexed as

Drug CarriersLiraglutideLungZinc OxideAdministration, InhalationAnimalsBiological AvailabilityDiabetes Mellitus, ExperimentalHumansMaleMiceParticle SizeRatsRats, Sprague-DawleySemaglutideDrug CarriersLiraglutideSemaglutideZinc OxideBarrier modulationMacrophage evasionMorphology engineeringMucus penetrationPeptide absorptionPulmonary deliveryZinc oxide

Identifiers

PMID41622258
PMCPMC13200438

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.